Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study-Reference-Cited by-同舟云学术

Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study

Published:2010-03-01 Issue:3 Volume:53 Page:323-332
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Molina Jean-Michel,Andrade-Villanueva Jaime,Echevarria Juan,Chetchotisakd Ploenchan,Corral Jorge,David Neal,Moyle Graeme,Mancini Marco,Percival Lisa,Yang Rong,Wirtz Victoria,Lataillade Max,Absalon Judith,McGrath Donnie

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference23 articles.

1. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras.;Crum;J Acquir Immune Defic Syndr,2006

2. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).;Gazzard;HIV Med,2006

3. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.;Hammer;JAMA,2006

4. Protease inhibitor-based regimens for HIV therapy: safety and efficacy.;Walmsley;J Acquir Immune Defic Syndr,2007

5. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.;Eron;Lancet,2006

Cited by 227 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. THERAPEUTIC STRATEGIES AND USE OF LOPINAVIR/RITONAVIR IN PATIENTS WITH HIGHLY RESISTANT HUMAN IMMUNODEFICIENCY VIRUS;FARMACIA;2024

2. Mechanism of action, resistance, interaction, pharmacokinetics, pharmacodynamics, and safety of fostemsavir;BMC Infectious Diseases;2024-02-23

3. BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022;HIV Medicine;2022-12

4. Part I: Interactive case: Hyperlipidemia management for special populations;JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY;2022-09

5. Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy;Drug Design, Development and Therapy;2022-01